AI-based Clinical Trials Solution Providers Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
AI-based Clinical Trials Solution Providers Market in 2025 is evaluated at USD 1.73 billion. The global Market size was worth around USD 1.47 billion in 2024 and is set to register a CAGR of more than 21.8%, exceeding USD 19.09 billion revenue by 2037. North America is likely to surpass largest share by 2037, attributed to increasing penetration of AI-based tools and rising government initiatives.
The growth of the market can be attributed to the increasing adoption of AI-based platforms to enhance the accuracy and productivity of clinical trials at different stages. According to the World Health Organization (WHO), the number of newly recruited trials registered on international clinical trial registry platforms (ICTRP) has been steadily increasing.
As the prevalence of various diseases increases, there is a need for new drug discoveries, which goes from a series of trials known as clinical trials, which tests potential treatments in human volunteers to see whether they should be approved for broader use in the general population. A treatment could be a drug, medical device, or biologic, such as a vaccine, blood product, or gene therapy. Potential treatments, however, must be studied in laboratory animals first to determine potential toxicity before they can be tried on people. As technology is advancing, AI-based clinical trials are becoming popular, where artificial intelligence and big data technology are used for extracting medical information. The market is growing owing to the prevalence of fetal diseases like cancer. According to studies, patient recruitment delays account for 85% of drug trial delays and 30% of early trial terminations. Patient eligibility and enrolment are two critical elements for the success of the overall drug study.
AI-based Clinical Trials Solution Providers Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Adoption of AI-based Platforms to Enhance Accuracy and Productivity at Different Stages - There is an increase in AI-based clinical trials for accuracy and productivity. Clinical trials are carefully designed, reviewed, and completed and need to be approved before they can start, which in turn requires higher accuracy, which AI-based platforms can easily do. According to the World Health Organization, the United States of America had the highest total number of trials registered during 1999–2021 (157,618), followed by China (80,333) and Japan (57,754). According to the same article, of trials categorized into a disease or condition, 81% were for non-communicable diseases, 15% for communicable, maternal, perinatal, and nutritional conditions, and 4% for injuries.
- Increasing Prevalence of Cancer Globally - There is an increase in the number of cancer cases globally, directly increasing the need for new drug development and treatment procedures for cancer. The higher drug development procedures increase clinical trials across the globe. According to the WHO, each year, approximately 400, 000 children develop cancer. The most common cancer varies among countries. Cervical cancer is the most common in 23 countries. Also, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or almost one in six deaths.
- Increasing Initiatives by Public and Private Sectors – Globally, numerous governments are driving initiatives to enhance the region's clinical trial environment. The Australian Government, for instance, is promoting initiatives to enhance the clinical trial environment in Australia, enhance health results, and boost foreign investment in the nation. The Clinical Trials Project Reference Group (CTPRG), formerly known as the Clinical Trials Jurisdictional Working Group (CTJWG), brings together senior officials from Commonwealth, State, and Territory health departments, as well as the National Health and Medical Research Council (NHMRC). In order to identify and implement actions and system redesigns that will enable a streamlined and consistent national approach to clinical trials in Australia, to improve health outcomes and enhance productivity.
- Presence of a Large Number of Registered Clinical Trials – Prevalence of large number of registered clinical trials is expected to drive the growth of this market in the forecast period. According to the World Health Organization, 59,964 clinical trials were conducted worldwide in 2021.
Challenges
- Strict Regulations Across the Globe – These solutions come with multiple strict codes of conduct that need to be followed and they are not the same in all regions. The strict regulations associated with them is considered to hamper the growth of the market in the upcoming times.
- Privacy Related Concerns
- Lack of AI Implementation Framework
AI-based Clinical Trials Solution Providers Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
21.8% |
|
Base Year Market Size (2024) |
USD 1.47 billion |
|
Forecast Year Market Size (2037) |
USD 19.09 billion |
|
Regional Scope |
|
AI-based Clinical Trials Solution Providers Segmentation
Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Neurological Disease)
The oncology segment is anticipated to garner the largest market share over the forecast period, owing to the increasing prevalence of cancer worldwide and the increasing number of drug trials. In 2019, oncology accounted for the most popular therapy area for non-industry-sponsored clinical trials, estimated for 26% of all clinical trials. In the recent times, there has been rise in drug based clinical trials in oncological research, this in turn have raised the demand for AI-based equipment in the clinical research. Moreover, growing number of market players opting for oncology-based simulated instruments for clinical preliminaries is driving the growth.
Clinical Trial Phase (Phase-I, Phase-II, Phase-III)
The Phase II segment is expected to account for the fastest market share in the forecast period. Phase II held a market share of 46.1% in 2022, owing to the prevalence of a large number of clinical trials. The growing incorporation of AI tools for immediate results from the desired outcome of drug trials and also the collection of data at the same timeis driving growth of the segment. Additionally, Phase I segment is anticipated to show the fastest growth rate in the forecast period. As phase I is advantageous for patient retention, better trial design and patient recruitment, the ai-based solution is expected to grow in the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Application |
|
|
By Clinical Trial Phase |
|
|
By End User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
AI-based Clinical Trials Solution Providers Industry - Regional Synopsis
North American Market Forecast
North America is estimated to hold significant AI-based clinical trials solution providers market share by 2037, owing to increasing penetration of AI-based tools and increasing government initiatives for adoption in different medical projects in the region. The region also has a rising corporate investment in artificial intelligence (AI) contributing market growth in the coming years. For instance, between 2018 and 2020, government agencies in the United States spent USD 1.9 billion on AI-related service obligations. Also, many ai-based startups opening their market in this region. For instance, BullFrog AI is a U.S. based ai startup, that creates bfLEAR an ai platform that allows precision medicines.
APAC Market Statistics
Asia Pacific is also anticipated to hold the significant revenue shareby the end of 2037, owing to the increasing number of AI-based startups. The region also has an increasing awareness of AI-based clinical trials. Owing to the growing demand for AI tools and supportive government programs that focuses on the implementation of AI in the healthcare sector.
Europe Market Forecast
Europe is anticipated to experience significant AI-based clinical trials solution providers market growth owing to the region's growing geriatric and target populations, expansion of key players' geographic markets, and active participation from governmental and nonprofit organizations.
Companies Dominating the AI-based Clinical Trials Solution Providers Landscape
- Unlearn.AI, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Saama Technologies, LLC.
- Antidote Technologies, Inc.
- Biosymetrics
- Pharmaceutical Pipeline Enhancement Strategies, LLC
- Deep 6 AI Inc.
- Innoplexus AG
- Mendel.ai
- Intelligencia
- Median Technologies
Recent Developments
- BioAge to start the phase 2 trial of BGE-175, which can reverse the effect of immunity aging amongst elderly population, to treat COVID-19.
- AiCure to join hands with OncoBay Clinical, a contract research organization, to provide oncology sponsors with scalable, AI-powered insights to improve patient care and optimize drug development.
- Report ID: 3859
- Published Date: May 08, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
AI-based Clinical Trials Solution Providers Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
